MEDICATION ACCESS BARRIERS FOR ELEXACAFTOR/TEZACAFTOR/IVACAFTOR-ELIGIBLE PEOPLE WITH CYSTIC FIBROSIS

被引：0
|
作者：
Dieni, O. [1 ]
Ryan, L. [1 ]
Stocks, A. [1 ]
Erdo, J. [1 ]
机构：
[1] Cyst Fibrosis Fdn, Bethesda, MD USA
来源：
PEDIATRIC PULMONOLOGY | 2020年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
811
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [1] Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis
    Nichols, David P.
    Paynter, Alex C.
    Heltshe, Sonya L.
    Donaldson, Scott H.
    Frederick, Carla A.
    Freedman, Steven D.
    Gelfond, Daniel
    Hoffman, Lucas R.
    Kelly, Andrea
    Narkewicz, Michael R.
    Pittman, Jessica E.
    Ratjen, Felix
    Rosenfeld, Margaret
    Sagel, Scott D.
    Schwarzenberg, Sarah Jane
    Singh, Pradeep K.
    Solomon, George M.
    Stalvey, Michael S.
    Clancy, John P.
    Kirby, Shannon
    Van Dalfsen, Jill M.
    Kloster, Margaret H.
    Rowe, Steven M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (05) : 529 - 539
  • [2] Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
    Fainardi, Valentina
    Cresta, Federico
    Sorio, Claudio
    Melotti, Paola
    Pesce, Emanuela
    Deolmi, Michela
    Longo, Francesco
    Karina, Kleinfelder
    Esposito, Susanna
    Pisi, Giovanna
    PEDIATRIC PULMONOLOGY, 2024, 59 (12) : 3383 - 3390
  • [3] Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
    Alicandro, Gianfranco
    Gramegna, Andrea
    Bellino, Federica
    Sciarrabba, Sathya Calogero
    Lanfranchi, Chiara
    Contarini, Martina
    Retucci, Mariangela
    Blasi, Francesco
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (06) : 1072 - 1079
  • [4] Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1589): : 5 - 7
  • [5] Racial and Ethnic Differences in Elexacaftor/Tezacaftor/Ivacaftor Provider Prescriptions for Variant- eligible People With Cystic Fibrosis
    Jordan, K.
    Vigers, T.
    Taylor-Cousar, J. L.
    Sagel, S. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [6] Cystic Fibrosis: Triple Therapy with Elexacaftor, Tezacaftor and Ivacaftor
    Lorenz, Judith
    PNEUMOLOGIE, 2022, 76 (03): : 153 - 153
  • [7] Tolerance of elexacaftor/tezacaftor/ivacaftor in Australians with cystic fibrosis
    Ruseckaite, Rasa
    Wark, Peter
    Pourghaderi, Ahmadreza
    Caruso, Marisa
    Ahern, Susannah
    RESPIROLOGY, 2024, 29 : 8 - 8
  • [8] Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis
    Beck, Michael R.
    Hornick, Douglas B.
    Pena, Tahuanty A.
    Singh, Sachinkumar B.
    Wright, Brittany A.
    PEDIATRIC PULMONOLOGY, 2023, 58 (05) : 1569 - 1573
  • [9] Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
    Williams, Cindy L.
    Billings, Joanna
    Mcgowan, Harriet
    Mcdevitt, Rebecca
    Esther Jr, Charles R.
    Mckinzie, Cameron J.
    Wilson, William S.
    Kam, Charissa W.
    PEDIATRIC PULMONOLOGY, 2025, 60 (03)
  • [10] Elucidating the Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Intolerance in People With Cystic Fibrosis
    Nielsen, Bibi Uhre
    Shaw, James A. M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
12345